| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
The Infectious Disease Research Institute, Seattle, WA 98104;
Medical School of Itajuba, Itajuba, Brazil;
Corixa Corporation, Seattle, WA 98104; and
Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA 15261
The development of an effective vaccine against Mycobacterium tuberculosis is a research area of intense interest. Mounting evidence suggests that protective immunity to M. tuberculosis relies on both MHC class II-restricted CD4+ T cells and MHC class I-restricted CD8+ T cells. By purifying polypeptides present in the culture filtrate of M. tuberculosis and evaluating these molecules for their ability to stimulate PBMC from purified protein derivative-positive healthy individuals, we previously identified a low-m.w. immunoreactive T cell Ag, Mtb 8.4, which elicited strong Th1 T cell responses in healthy purified protein derivative-positive human PBMC and in mice immunized with recombinant Mtb 8.4. Herein we report that Mtb 8.4-specific T cells can be detected in mice immunized with the current live attenuated vaccine, Mycobacterium bovis-bacillus Calmette-Guérin as well as in mice infected i.v. with M. tuberculosis. More importantly, immunization of mice with either plasmid DNA encoding Mtb 8.4 or Mtb 8.4 recombinant protein formulated with IFA elicited strong CD4+ T cell and CD8+ CTL responses and induced protection on challenge with virulent M. tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB.
This article has been cited by other articles:
|
|
 |
|
  L. Majlessi, M. Simsova, Z. Jarvis, P. Brodin, M.-J. Rojas, C. Bauche, C. Nouze, D. Ladant, S. T. Cole, P. Sebo, et al. An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis Infect. Immun., April 1, 2006; 74(4): 2128 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mukherjee, S. S. Kashino, Y. Zhang, N. Daifalla, V. Rodrigues Jr, S. G. Reed, and A. Campos-Neto Cloning of the Gene Encoding a Protective Mycobacterium tuberculosis Secreted Protein Detected In Vivo during the Initial Phases of the Infectious Process J. Immunol., October 15, 2005; 175(8): 5298 - 5305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Shin, C.-F. Chang, C.-D. Chang, S. P. McDonough, B. Thompson, H. S. Yoo, and Y.-F. Chang In Vitro Cellular Immune Responses to Recombinant Antigens of Mycobacterium avium subsp. paratuberculosis Infect. Immun., August 1, 2005; 73(8): 5074 - 5085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Sable, I. Verma, D. Behera, and G. K. Khuller Human immune recognition-based multicomponent subunit vaccines against tuberculosis Eur. Respir. J., May 1, 2005; 25(5): 902 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-H. Hovav, Y. Fishman, and H. Bercovier Gamma Interferon and Monophosphoryl Lipid A-Trehalose Dicorynomycolate Are Efficient Adjuvants for Mycobacterium tuberculosis Multivalent Acellular Vaccine Infect. Immun., January 1, 2005; 73(1): 250 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Mollenkopf, L. Grode, J. Mattow, M. Stein, P. Mann, B. Knapp, J. Ulmer, and S. H. E. Kaufmann Application of Mycobacterial Proteomics to Vaccine Design: Improved Protection by Mycobacterium bovis BCG Prime-Rv3407 DNA Boost Vaccination against Tuberculosis Infect. Immun., November 1, 2004; 72(11): 6471 - 6479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Derrick, C. Repique, P. Snoy, A. L. Yang, and S. Morris Immunization with a DNA Vaccine Cocktail Protects Mice Lacking CD4 Cells against an Aerogenic Infection with Mycobacterium tuberculosis Infect. Immun., March 1, 2004; 72(3): 1685 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vekemans, M. O. C. Ota, J. Sillah, K. Fielding, M. R. Alderson, Y. A. W. Skeiky, W. Dalemans, K. P. W. J. McAdam, C. Lienhardt, and A. Marchant Immune Responses to Mycobacterial Antigens in the Gambian Population: Implications for Vaccines and Immunodiagnostic Test Design Infect. Immun., January 1, 2004; 72(1): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Kohler, D. M. Stone, M. T. Hines, B. A. Byrne, D. C. Alperin, L. K. Norton, and S. A. Hines Rhodococcus equi Secreted Antigens Are Immunogenic and Stimulate a Type 1 Recall Response in the Lungs of Horses Immune to R. equi Infection Infect. Immun., November 1, 2003; 71(11): 6329 - 6337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-H. Hovav, J. Mullerad, L. Davidovitch, Y. Fishman, F. Bigi, A. Cataldi, and H. Bercovier The Mycobacterium tuberculosis Recombinant 27-Kilodalton Lipoprotein Induces a Strong Th1-Type Immune Response Deleterious to Protection Infect. Immun., June 1, 2003; 71(6): 3146 - 3154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Day, Y. Zhang, P. Clair, K. H. Grabstein, M. Mazel, A. R. Rees, M. Kaczorek, and J. Temsamani Induction of Antigen-Specific CTL Responses Using Antigens Conjugated to Short Peptide Vectors J. Immunol., February 1, 2003; 170(3): 1498 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B Young and G. R Stewart Tuberculosis vaccines Br. Med. Bull., July 1, 2002; 62(1): 73 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed Vaccination with Plasmid DNA Encoding TSA/LmSTI1 Leishmanial Fusion Proteins Confers Protection against Leishmania major Infection in Susceptible BALB/c Mice Infect. Immun., June 1, 2002; 70(6): 2828 - 2836. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
